Sign Up to like & get
recommendations!
2
Published in 2022 at "Human Brain Mapping"
DOI: 10.1002/hbm.25774
Abstract: This study sought to identify a reference tissue‐based quantification approach for improving the statistical power in detecting changes in brain glucose metabolism, amyloid, and tau deposition in Alzheimer's disease studies. A total of 794, 906,…
read more here.
Keywords:
reference;
disease;
florbetapir 18f;
18f florbetapir ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Brain"
DOI: 10.1093/brain/awac004
Abstract: Abstract Tau accumulation starts during the preclinical phase of Alzheimer’s disease and is closely associated with cognitive decline. For preventive purposes, it is important to identify factors associated with tau accumulation and spread. Studying genetically…
read more here.
Keywords:
genetically identical;
pathology;
twin pairs;
distribution ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2019 at "Neurology"
DOI: 10.1212/wnl.0000000000006875
Abstract: Objective To examine the cross-sectional associations between regional tau, β-amyloid (Aβ), and cortical thickness and neuropsychological function across the preclinical and clinical spectrum of Alzheimer disease (AD). Methods We included 106 participants from the Swedish…
read more here.
Keywords:
cortical thickness;
18f flutemetamol;
alzheimer disease;
thickness ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Journal of Nuclear Medicine"
DOI: 10.2967/jnumed.122.263926
Abstract: Visual Abstract Semiquantitative PET measures such as SUV ratio (SUVr) have several advantages over quantitative measures, such as practical applicability and relative computational simplicity. However, SUVr may potentially be affected by changes in blood flow,…
read more here.
Keywords:
cerebral blood;
suvr;
pet;
blood flow ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2023 at "Journal of Alzheimer's Disease"
DOI: 10.3233/jad-230032
Abstract: Background: 18F-flortaucipir PET received FDA approval to visualize aggregated neurofibrillary tangles (NFTs) in brains of adult patients with cognitive impairment being evaluated for Alzheimer’s disease (AD). However, manufacturer’s guidelines for visual interpretation of 18F-flortaucipir PET…
read more here.
Keywords:
tau pet;
clinical assessment;
visual interpretation;
interpretation ... See more keywords